Gyant, which provides AI-enabled remote patient-doctor engagement and symptom checking tools for hospitals and healthcare providers, raises $13.6M Series A
Last Chance: Register for Transform, VB's AI event of the year, hosted online July 15-17. — Gyant, whose AI-enabled health platform …
Context & Ripple Effects
Gyant's $13.6M Series A lands at the peak of the pandemic-era telehealth funding run: it follows Tyto Care's $50M round in April 2020 and precedes 98point6's $118M Series E that October. The category had already proven itself pre-pandemic — Current Health's $11.5M Series A in late 2019 showed investors would back remote patient management before COVID made it urgent.
What distinguishes Gyant is its position at the hospital 'front door': symptom checking and patient-doctor engagement sold to institutions, not consumers. The rounds that followed confirm both the category's scale and its ceiling — K Health's $132M Series E in January 2021 dwarfed Gyant's raise on the consumer side, while Counsel Health's $25M Series A in 2025 shows chatbot-plus-physician models were still being funded years later.
First-order effects
- Hospitals and providers evaluating digital front-door tools now have a newly capitalized vendor in Gyant, but one entering against far larger rivals — 98point6 and K Health each raised multiples of this round within months of it.
Second-order effects
- The funding gap forces Gyant to compete on workflow integration with hospital systems rather than consumer acquisition, where the big raises are concentrated — pushing symptom-checker startups toward provider-side specialization or consolidation.
Third-order effects
- The persistence of hybrid models like Counsel Health's chatbot-with-physicians structure suggests pure AI triage did not displace clinicians; instead, engagement and triage software is becoming an embedded procurement line for health systems rather than a standalone product category.
The trend: AI-powered patient triage and engagement is consolidating from venture-funded point solutions into embedded infrastructure inside health systems, with capital concentrating heavily at the later stages of the stack.